Effectiveness of Chemotherapy in Metastatic or Recurrent Carcinoma Cervix
Status:
Unknown status
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
Experience with substituting carboplatin for cisplatin is limited in advanced and recurrent
cervix cancer and there has been no counterpart to GOG 158, which documented therapeutic
equivalency of cisplatin/paclitaxel and carboplatin/paclitaxel for treatment of ovarian
cancer, performed in a cervix cancer population.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
All India Institute of Medical Sciences, New Delhi